Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
June 29, 2015
Blueprint Medicines Added to Russell 2000®, 3000® and Global Indexes … [Read More...]
June 22, 2015
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate … [Read More...]